Bionomics ( (BNOX) ) has issued an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Neuphoria Therapeutics Inc. has completed its redomiciliation, transferring governance from Bionomics’ organizational documents to Neuphoria’s new Certificate of Incorporation and bylaws. This strategic move positions Neuphoria as the successor issuer to Bionomics, with its shares now registered under the Exchange Act, which may influence its governance structure and shareholder rights.
More about Bionomics
YTD Price Performance: -83.65%
Average Trading Volume: 9,738,552
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.72M
Find detailed analytics on BNOX stock on TipRanks’ Stock Analysis page.